CN111796043B - Papaverine hydrochloride powder injection for injection and quality detection method thereof - Google Patents
Papaverine hydrochloride powder injection for injection and quality detection method thereof Download PDFInfo
- Publication number
- CN111796043B CN111796043B CN202010822009.6A CN202010822009A CN111796043B CN 111796043 B CN111796043 B CN 111796043B CN 202010822009 A CN202010822009 A CN 202010822009A CN 111796043 B CN111796043 B CN 111796043B
- Authority
- CN
- China
- Prior art keywords
- papaverine
- impurity
- injection
- solution
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 160
- 239000007924 injection Substances 0.000 title claims abstract description 160
- 239000000843 powder Substances 0.000 title claims abstract description 127
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 229960003207 papaverine hydrochloride Drugs 0.000 title claims abstract description 60
- 238000001514 detection method Methods 0.000 title claims abstract description 11
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims abstract description 240
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims abstract description 120
- 229960001789 papaverine Drugs 0.000 claims abstract description 120
- 239000012535 impurity Substances 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 90
- 239000000243 solution Substances 0.000 claims abstract description 82
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 41
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims abstract description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims abstract description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 69
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 52
- 238000002360 preparation method Methods 0.000 claims description 40
- 239000007788 liquid Substances 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 35
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 claims description 33
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 claims description 33
- 229940043353 maltol Drugs 0.000 claims description 33
- 238000004108 freeze drying Methods 0.000 claims description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 29
- 239000012085 test solution Substances 0.000 claims description 29
- 239000012528 membrane Substances 0.000 claims description 28
- 239000008215 water for injection Substances 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 27
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 24
- 229930195725 Mannitol Natural products 0.000 claims description 24
- 239000000594 mannitol Substances 0.000 claims description 24
- 235000010355 mannitol Nutrition 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 22
- 239000012046 mixed solvent Substances 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 19
- 235000004279 alanine Nutrition 0.000 claims description 19
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 18
- 238000007865 diluting Methods 0.000 claims description 17
- 239000012088 reference solution Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 15
- 229940009662 edetate Drugs 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 11
- 239000008176 lyophilized powder Substances 0.000 claims description 11
- 230000014759 maintenance of location Effects 0.000 claims description 10
- 229930182555 Penicillin Natural products 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- 238000012937 correction Methods 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 9
- 229940049954 penicillin Drugs 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 238000003825 pressing Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 235000006408 oxalic acid Nutrition 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims description 4
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 4
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000013558 reference substance Substances 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims 6
- 229960001855 mannitol Drugs 0.000 claims 4
- UEAVLBXLOZNDHT-UHFFFAOYSA-K calcium;sodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEAVLBXLOZNDHT-UHFFFAOYSA-K 0.000 claims 2
- 238000005374 membrane filtration Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 28
- 238000011003 system suitability test Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 238000009472 formulation Methods 0.000 description 22
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 17
- 230000000202 analgesic effect Effects 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 13
- 238000001471 micro-filtration Methods 0.000 description 13
- ZQCGNPNWSMJDEF-UHFFFAOYSA-N (-)-norargemonine Chemical compound C1C2=CC(OC)=C(OC)C=C2C2CC(C=C(C(=C3)O)OC)=C3C1N2C ZQCGNPNWSMJDEF-UHFFFAOYSA-N 0.000 description 12
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 10
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229960000715 nimodipine Drugs 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 208000001286 intracranial vasospasm Diseases 0.000 description 9
- 239000003002 pH adjusting agent Substances 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000005392 Spasm Diseases 0.000 description 7
- 206010047163 Vasospasm Diseases 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000010410 reperfusion Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- ZQCGNPNWSMJDEF-HOTGVXAUSA-N (-)-Norargemonine Natural products C1C2=CC(OC)=C(OC)C=C2[C@@H]2CC(C=C(C(=C3)O)OC)=C3[C@H]1N2C ZQCGNPNWSMJDEF-HOTGVXAUSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940088679 drug related substance Drugs 0.000 description 6
- 210000001105 femoral artery Anatomy 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 description 6
- 230000001148 spastic effect Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 101800004490 Endothelin-1 Proteins 0.000 description 5
- 210000004004 carotid artery internal Anatomy 0.000 description 5
- 230000000916 dilatatory effect Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 4
- 102400000686 Endothelin-1 Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229960003150 bupivacaine Drugs 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 230000010339 dilation Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 210000002321 radial artery Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000003071 vasodilator agent Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 206010062575 Muscle contracture Diseases 0.000 description 3
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 208000006906 Vascular Ring Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- -1 amide compounds Chemical class 0.000 description 3
- 210000001841 basilar artery Anatomy 0.000 description 3
- 210000003461 brachial plexus Anatomy 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 208000006111 contracture Diseases 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- UCJDFFOXXPPGLJ-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-3,4-dihydroisoquinoline Chemical class C1=C(OC)C(OC)=CC=C1CC1=NCCC2=CC(OC)=C(OC)C=C12 UCJDFFOXXPPGLJ-UHFFFAOYSA-N 0.000 description 2
- QGQXAMBOYWULFX-LZWSPWQCSA-N 2-morpholin-4-ylethyl (e)-6-(4,6-dihydroxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound OC=1C=2C(=O)OCC=2C(C)=C(O)C=1C\C=C(/C)CCC(=O)OCCN1CCOCC1 QGQXAMBOYWULFX-LZWSPWQCSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 239000008896 Opium Substances 0.000 description 2
- ZKLXUUYLEHCAMF-UHFFFAOYSA-N Oripavine Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(O)C5=C4C23C1O5 ZKLXUUYLEHCAMF-UHFFFAOYSA-N 0.000 description 2
- 235000008753 Papaver somniferum Nutrition 0.000 description 2
- 240000001090 Papaver somniferum Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000007428 craniotomy Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940124274 edetate disodium Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229960001027 opium Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004648 relaxation of smooth muscle Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 210000003752 saphenous vein Anatomy 0.000 description 2
- 230000008326 skin blood flow Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000002385 vertebral artery Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101100515513 Arabidopsis thaliana XI-E gene Proteins 0.000 description 1
- 101100515516 Arabidopsis thaliana XI-H gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000002532 foramen magnum Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 206010037628 pylorospasm Diseases 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a papaverine hydrochloride powder injection for injection and a quality detection method thereof, in particular to a method for determining the content of an impurity A, B, C, D, E, F in the powder injection by using a high performance liquid chromatography, which comprises the following steps: measuring according to the specification of 0512 high performance liquid chromatography of the four parts of the 2015 edition of Chinese pharmacopoeia; an Eclipse XDB-C8 column is used as a chromatographic column; mobile phase: the pH of the mobile phase A which is 3.4g/L potassium dihydrogen phosphate solution is adjusted to 3.0 by dilute phosphoric acid, the mobile phase B is acetonitrile, and the mobile phase C is methanol; adopting a gradient elution program to detect the wavelength of 238 nm; the separation degree between the impurity A peak and the papaverine peak in the system suitability test is not less than 1.5. The invention also relates to a papaverine hydrochloride powder injection for injection. The method and the papaverine hydrochloride powder injection for injection have excellent technical effects as described in the specification.
Description
Technical Field
The invention belongs to the technical field of medicines, relates to an opiate alkaloid used as a vasodilator, and particularly relates to a freeze-dried powder injection of papaverine. The invention also relates to a quality detection method of the papaverine freeze-dried powder injection, in particular to a method for determining the content of specific impurities in the papaverine freeze-dried powder injection. The freeze-dried powder injection of papaverine of the present invention exhibits excellent technical effects as described herein.
Background
Papaverine, Hydrochloride commonly used in clinic, having the English name of Papaverine Hydrochloride, wherein the molecular formula of the Papaverine Hydrochloride is C20H21NO4 & HCl, the molecular weight is 375.85, the chemical name is 1- [ (3, 4-dimethoxyphenyl) methyl ] -6, 7-dimethoxyisoquinoline Hydrochloride, and the chemical structural formula of the Papaverine Hydrochloride is as follows:
papaverine hydrochloride is a vasodilator, and is a nonspecific smooth muscle relieving agent, especially for pulmonary artery, sinus artery, and large blood vessel to produce nonspecific artery dilatation and smooth muscle relaxation. It acts directly on smooth muscle cells, inhibits phosphodiesterase, increases intracellular Cyclic Adenosine Monophosphate (CAMP) concentration, which removes catalase from vascular smooth muscle out of the cytoplasm, producing a direct smooth muscle relaxation effect without neural involvement. Large doses of papaverine hydrochloride can cause hypotension and also tachycardia. Papaverine hydrochloride also inhibits visceral conduction, acts directly on myocytes, and prolongs refractory period. Has no effect on the central nervous system.
Papaverine hydrochloride is mainly used for cerebral thrombosis, pulmonary embolism, acro-arterial spasm, arterial embolic pain and the like. Has insignificant curative effect on hypertension, angina pectoris, pylorospasm, biliary colic, intestinal colic, bronchial asthma and the like under common dosage.
The oral administration bioavailability of the papaverine hydrochloride is 68-89%, the first pass effect is 70%, the controlled release dosage form is 22-29%, and the peak plasma concentration is reached 1-2 hours after the administration. The papaverine hydrochloride is orally taken for 3 times a day, and the dosage is 30-60 mg each time. The dose is 200mg once and 600mg daily. Intramuscular injection or intravenous drip: 30mg for each time, 90-120 mg per day, and the dosage should not exceed 300mg per day.
Papaverine has been synthesized in 1969 abroad, and its chemical synthesis is realized in 1980 and is used clinically. Tan Zhongqin literature (Tan Zhongqin, etc., synthetic route illustration of papaverine hydrochloride, university of Wuhan engineering, Vol.42No.1Feb.2020, 42(1):1-7) reviews various synthetic routes of papaverine hydrochloride in detail, and the method reviews the synthetic methods of papaverine hydrochloride and key intermediates 16 and 21 (synthetic routes 1-3) by using different raw material medicines and process routes, and especially combines the characteristics of the currently adopted synthetic routes (synthetic routes 4-5) in China with the national conditions of China. Papaverine hydrochloride currently used in various countries is mostly prepared by the following process route:
further salifying with hydrochloric acid to form papaverine hydrochloride.
Residual amide compounds and dihydropapaverine compounds in the bulk drug are of particular concern.
In addition, degradation products in the formulation are of particular concern and the formulation may degrade during prolonged periods of presence to produce a poppy alcohol of the formula:
in particular, the present inventors have found that the lyophilized powder injection with mannitol added exhibits an increase in the content of papaverol necessary to be particularly noted during long-term storage.
There remains a need in the art for new methods for preparing formulations of papaverine hydrochloride, such as lyophilized powder injections thereof.
Disclosure of Invention
The invention aims to provide a method for preparing papaverine hydrochloride preparation with excellent performance, such as freeze-dried powder injection thereof. The present inventors have surprisingly found that a papaverine freeze-dried powder injection comprising mannitol prepared by the method of the present invention exhibits excellent properties such as excellent chemical stability, particularly in which an increase in papaverol is significantly suppressed, and have completed the present invention based on such findings.
To this end, the invention provides in a first aspect a pharmaceutical composition comprising papaverine and a pharmaceutically acceptable excipient.
The pharmaceutical composition according to the first aspect of the invention, wherein the papaverine is the hydrochloride salt thereof.
The pharmaceutical composition according to the first aspect of the present invention, wherein the pharmaceutical excipient comprises mannitol.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to mannitol is 30: 15 to 500.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to mannitol is 30: 20 to 250 parts.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to mannitol is 30: 30-200.
The pharmaceutical composition according to the first aspect of the present invention, wherein the pharmaceutical excipient comprises edetate, such as edetate disodium, calcium disodium edetate.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to edetate is 30: 2 to 10.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to edetate is 30: 3 to 8.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to edetate is 30: 4 to 6.
The pharmaceutical composition according to the first aspect of the present invention, further comprising alanine.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to alanine is 30: 10 to 20.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to alanine is 30: 10 to 18.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to alanine is 30: 10 to 16.
The pharmaceutical composition according to the first aspect of the present invention, further comprising maltol.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to maltol is 30: 2 to 10.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to maltol is 30: 2 to 7.
The pharmaceutical composition according to the first aspect of the invention, wherein the weight ratio of papaverine to maltol is 30: 2 to 4.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, further comprising an acid-base modifier.
The pharmaceutical composition according to the first aspect of the present invention is a freeze-dried powder injection.
The pharmaceutical composition according to the first aspect of the present invention is a freeze-dried powder injection, which has a solid content of 2 to 20% in a solution before freeze-drying, for example, which has a solid content of 3 to 15% in a solution before freeze-drying.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the amount of the pH regulator is such that when the lyophilized powder for injection is dissolved in water for injection to form a solution containing papaverine hydrochloride at a concentration of 15mg/ml, the pH of the solution is within a range of 2.5 to 4.0, for example, the pH of the solution is within a range of 3.0 to 4.0. The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the ph modifying agent is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, hydrochloric acid, phosphoric acid, nitric acid, sulfuric acid, or a combination thereof. In one embodiment, the pH adjusting agent is a hydrochloric acid solution or a sodium hydroxide solution, such as a 1M hydrochloric acid solution or a 1M sodium hydroxide solution.
For freeze-dried powder injection, the liquid medicine is sterilized by filtering through a microporous filter membrane in advance before freeze-drying, the sterilized liquid medicine is subpackaged into glass bottles, and then the subpackaged liquid medicine is sent into a freeze-dryer for freeze-drying, which is a process for preparing a conventional freeze-dried powder injection well known to those skilled in the art. It has been surprisingly found that the rate of growth of alcoholic impurities can be significantly inhibited when both alanine and maltol are used simultaneously, which is completely unexpected in the prior art.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the formulated drug solution is sterilized by filtration through a microporous membrane before freeze-drying. In one embodiment, the microfiltration membrane comprises at least a microfiltration membrane having a pore size of 0.22 μm. In one embodiment, the microfiltration membrane is adapted to filter sterilise the liquid drug at least 2 times, for example 2-4 times, through a microfiltration membrane having a pore size of 0.22 μm.
The pharmaceutical composition according to any of the embodiments of the first aspect of the present invention, wherein the microfiltration membrane is a microfiltration membrane for the production of an aqueous injection formulation, such as but not limited to a microfiltration membrane selected from the group consisting of: cellulose acetate membrane material, cellulose nitrate membrane material, polyamide membrane material, polycarbonate membrane material, polysulfone membrane material and polytetrafluoroethylene membrane material.
As is well known, freeze-dried powder injection (usually, referred to as freeze-dried powder injection or freeze-dried powder injection) obtained by low-temperature freeze-vacuum drying is a powder or a block which is substantially anhydrous (usually, the water content is less than 5%, particularly, usually, less than 3%) and is obtained by dissolving each material in a solvent (usually, in water) to prepare a solution, freezing the solution at a low temperature, and then performing vacuum-pumping, sublimation and drying. Therefore, the pH of the solid lyophilizate is usually controlled by adjusting the pH of the solution during the formulation process; or can be controlled by adjusting the prescription so that the pH value of the obtained solid lyophilizate is controlled under the specified dissolving/diluting degree (the pH value of the solid lyophilizate is controlled); the latter method is generally more commonly used, for example, many lyophilized powder injections carried in pharmacopoeia control the pH value of the preparation in this way, and the pH value of the product can be controlled in this way, and the pH value of the final product can be only regulated without specifically specifying the prescription amount of the pH regulator. Also suitable for use in the present invention is a lyophilized powder for injection pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the amount of the optional pH adjusting agent is an amount such that when the lyophilized powder for injection is dissolved in water for injection to form a solution containing papaverine hydrochloride at a concentration of 15mg/ml, the pH of the solution is in the range of 2.5 to 4.0, for example, the pH of the solution is in the range of 3.0 to 4.0.
A pharmaceutical composition according to any one of the embodiments of the first aspect of the invention, prepared substantially by the steps comprising:
(a) weighing papaverine hydrochloride and pharmaceutic adjuvant according to the prescription amount, adding a proper amount of water for injection to dissolve, adding active carbon, stirring, filtering and decarburizing;
(b) supplementing the water for injection to the prescription amount, uniformly stirring, measuring the pH value of the solution and optionally measuring the content of active ingredients, and if necessary, adjusting the pH value to 2.5-4.0 by using an acid-base regulator, preferably 3.0-4.0;
(c) sterilizing and filtering the liquid medicine by using a microporous filter membrane, and filling the liquid medicine into a penicillin bottle;
(d) freeze drying to remove water, and pressing.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the filtered filtrate obtained in step (c) has a solid content of 2-20% (w/v), preferably 3-15%.
The pharmaceutical composition according to any one of the embodiments of the first aspect of the present invention, wherein the "adding an appropriate amount of water for injection" in step (a) means adding 50-90% of the volume of water for injection.
The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the mannitol may also be replaced with the following adjuvants: lactose, sucrose, glucose, sorbitol, glycine, dextran, sodium chloride, and combinations thereof.
Further, the present invention provides in a second aspect a process for preparing a pharmaceutical composition for injection, such as a pharmaceutical composition according to the first aspect of the present invention, comprising the steps of:
(a) weighing papaverine hydrochloride and pharmaceutic adjuvant according to the prescription amount, adding a proper amount of water for injection to dissolve, adding active carbon, stirring, filtering and decarburizing;
(b) supplementing the water for injection to the prescription amount, uniformly stirring, measuring the pH value of the solution and optionally measuring the content of active ingredients, and if necessary, adjusting the pH value to 2.5-4.0 by using an acid-base regulator, preferably 3.0-4.0;
(c) sterilizing and filtering the liquid medicine by using a microporous filter membrane, and filling the liquid medicine into a penicillin bottle;
(d) freeze drying to remove water, and pressing.
In the present invention, generally speaking, when the pH of the drug solution is directly adjusted to be within the range of 2.5 to 4.0 in the step (b), when the powder injection prepared by the method is dissolved into a solution containing papaverine hydrochloride with a concentration of 15mg/ml by water, the pH of the solution is also within the range of 2.5 to 4.0, and the pH of the step (b) is substantially the same as the pH of the solution obtained by the dissolution according to the above method (the difference is usually not more than 0.1 pH unit).
The method according to any one of the embodiments of the second aspect of the present invention, wherein the microfiltration membrane comprises at least a microfiltration membrane having a pore size of 0.22 μm.
The method according to any embodiment of the second aspect of the present invention, wherein said microfiltration membrane filter sterilisation at least 2 times, such as 2-4 times, of the liquid drug is filter sterilised through a microfiltration membrane having a pore size of 0.22 μm.
The method according to any embodiment of the second aspect of the invention, wherein the pharmaceutical excipient comprises mannitol.
The method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to mannitol is 30: 15 to 500.
The method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to mannitol is 30: 20 to 250 parts.
The method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to mannitol is 30: 30-200.
The method according to any embodiment of the second aspect of the invention, wherein the pharmaceutical excipient comprises edetate, e.g. edetate disodium, calcium disodium edetate.
A method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to edetate is 30: 2 to 10.
A method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to edetate is 30: 3 to 8.
A method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to edetate is 30: 4 to 6.
The method according to any one of the embodiments of the second aspect of the present invention, further comprising alanine.
The method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to alanine is 30: 10 to 20.
The method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to alanine is 30: 10 to 18.
The method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to alanine is 30: 10 to 16.
The method according to any one of the embodiments of the second aspect of the present invention, further comprising maltol.
The method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to maltol is 30: 2 to 10.
The method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to maltol is 30: 2 to 7.
The method according to any one of the embodiments of the second aspect of the invention, wherein the weight ratio of papaverine to maltol is 30: 2 to 4.
The method according to any embodiment of the second aspect of the present invention, wherein an acid-base modifier is further included.
The method according to any embodiment of the second aspect of the present invention, wherein the amount of the pH regulator is such that when the lyophilized powder for injection is dissolved in water for injection to form a solution containing papaverine hydrochloride at a concentration of 15mg/ml, the pH of the solution is within a range of 2.5 to 4.0, for example, the pH of the solution is within a range of 3.0 to 4.0. The pharmaceutical composition according to any embodiment of the first aspect of the present invention, wherein the ph modifying agent is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, hydrochloric acid, phosphoric acid, nitric acid, sulfuric acid, or a combination thereof. In one embodiment, the pH adjusting agent is a hydrochloric acid solution or a sodium hydroxide solution, such as a 1M hydrochloric acid solution or a 1M sodium hydroxide solution.
Further, the third aspect of the invention provides the application of the combination of alanine and maltol in preparing the pharmaceutical composition of the papaverine hydrochloride freeze-dried powder injection for injection.
The use according to any of the embodiments of the third aspect of the present invention, wherein said alanine and maltol are both used in combination to inhibit the rate of growth of alcoholic impurities in the pharmaceutical composition.
The use according to any embodiment of the third aspect of the present invention, wherein the pharmaceutical composition is as described in any embodiment of the first aspect of the present invention.
Further, the present invention provides a method for quality detection of the pharmaceutical composition according to any one of the embodiments of the first aspect of the present invention, which comprises determining the content of the impurity A, B, C, D, E, F in the powder injection by using high performance liquid chromatography.
The method according to any embodiment of the fourth aspect of the present invention, comprising the operations of:
measuring according to the specification of 0512 high performance liquid chromatography of the four parts of the 2015 edition of Chinese pharmacopoeia;
mixing solvent: acetonitrile/mobile phase a (20/80, v/v);
test solutions: for the raw material medicine, 20.0mg of a sample is dissolved in a mixed solvent, and then the mixed solvent is used for diluting to 10.0 mL; for the pharmaceutical composition, a test sample containing 20.0mg of papaverine hydrochloride is dissolved in a mixed solvent, and then diluted to 10.0mL by the mixed solvent;
reference solution (a): diluting 1.0mL of test solution to 100.0mL by using a mixed solvent, and then diluting 1.0mL of the test solution to 10.0mL by using the mixed solvent;
reference solution (b): dissolving 12mg of narcotine (impurity A) reference substance into 1.0mL of test solution, and then diluting the solution to 100.0mL by using a mixed solvent;
a chromatographic column: eclipse XDB-C8 column, 4.6X 250mm, 5 μm; mobile phase: the pH of the mobile phase A which is 3.4g/L potassium dihydrogen phosphate solution is adjusted to 3.0 by dilute phosphoric acid, the mobile phase B is acetonitrile, and the mobile phase C is methanol; elution procedure:
flow rate: 1 mL/min;
detection wavelength of spectrophotometer: 238 nm;
sample introduction amount: 10 mu L of the solution;
the relative retention times compared to papaverine are: 0.67 + -0.02 RRT of impurity E, 0.74 + -0.02 RRT of impurity C, 0.81 + -0.02 RRT of impurity B, 0.90 + -0.02 RRT of impurity A, 1.11 + -0.02 RRT of impurity F, and 1.21 + -0.02 RRT of impurity D;
and (3) testing the applicability of the system: using a reference solution (b) with a separation between the impurity a peak and the papaverine peak of not less than 1.5;
calculating the content of the impurity A, B, C, D, E, F by comparing the main peak area of the reference solution (a) with the peak area of the impurity appearing in the test solution and combining a correction factor; in calculating the content, the peak areas of the following impurities, if present, were multiplied by the corresponding correction factors: impurity a ═ 6.2, impurity C ═ 2.7, and impurity D ═ 0.5 (the remaining impurities, if present, had a correction factor of 1).
The process according to any of the embodiments of the fourth aspect of the present invention, wherein impurity A, B, C, D, E, F is:
the method according to any one of the embodiments of the fourth aspect of the present invention, wherein the test solution is prepared as follows: placing a powder injection test sample containing 200.0mg of papaverine hydrochloride into a 25mL stoppered test tube, precisely adding 10mL of diethyl ether and 10mg of oxalic acid, sealing the test tube, carrying out vortex treatment for 25min, centrifuging, precisely measuring 1mL of supernatant, placing the supernatant into a 10mL measuring flask, volatilizing the supernatant, adding a mixed solvent to dissolve the supernatant, and diluting the supernatant to 10.0mL to obtain a test solution.
The method according to any one of the embodiments of the fourth aspect of the invention, wherein the relative retention time of each impurity compared to papaverine is: RRT of impurity E is 0.673, RRT of impurity C is 0.741, RRT of impurity B is 0.812, RRT of impurity a is 0.896, RRT of impurity F is 1.107, and RRT of impurity D is 1.214.
A process according to any one of the fourth aspect of the invention wherein the papaverine has a retention time of 24 ± 1 min.
The method according to any one of the embodiments of the fourth aspect of the present invention, for determining the content of impurity C.
Any embodiment of any aspect of the invention may be combined with other embodiments, as long as they do not contradict. Furthermore, in any embodiment of any aspect of the invention, any feature may be applicable to that feature in other embodiments, so long as they do not contradict. The invention is further described below.
All documents cited herein are incorporated by reference in their entirety and to the extent such documents do not conform to the meaning of the present invention, the present invention shall control. Further, the various terms and phrases used herein have the ordinary meaning as is known to those skilled in the art, and even though such terms and phrases are intended to be described or explained in greater detail herein, reference is made to the term and phrase as being inconsistent with the known meaning and meaning as is accorded to such meaning throughout this disclosure.
According to the present invention, the term "pharmaceutical excipient" may also be referred to as excipient, filler, etc.
As used herein, "pharmaceutical excipient" refers to an excipient that can be used to formulate a drug that has substantially no adverse effect on an organism and is generally tolerated by an organism.
In the invention, after the preferable freeze-dried powder injection of the invention is prepared into a solution containing 15mg of active ingredient in each 1ml by water, the solution is measured according to the method under item VI H in appendix VI H of the second part of the 2010 version of Chinese pharmacopoeia, namely the pH value measurement method, or the measurement method can be carried out according to the methods of pharmacopoeias of other versions.
While it is understood by those skilled in the art that the excipient of the present invention may be any excipient useful in lyophilization, particularly mannitol, lactose, sucrose, glucose, sorbitol, glycine, dextran, sodium chloride, and combinations thereof, in the present invention, especially preferred excipients are mannitol, lactose, dextran, and the like.
The preparation process of freeze-dried powder injection is a well-known pharmaceutical technology, such as two schematic freeze-drying curves shown as a freeze-drying curve A and a freeze-drying curve B described in CN 104666253A. In the following specific examples in the preparation of freeze-dried powder injections, the lyophilization profile used is lyophilization profile a, unless otherwise specified.
The water content in the freeze-dried powder injection is generally below 8%, preferably below 5%, more preferably below 3%. Moisture control can be controlled by appropriate adjustment of the freeze-drying program. The moisture content of the freeze-dried powder injection can be determined according to a number of known methods, such as loss-on-drying. In the following specific examples of the powder injection of the present invention, the water content is controlled to be 1.5 to 2.5% by freeze-drying process unless otherwise specified.
In the present invention, in order to adjust the pH of the drug solution as necessary, an appropriate pH adjusting agent (also referred to as an acid-base adjusting agent in the present invention) may be added to the composition. Although the present inventors have conducted adjustment only with a strong acid or strong alkali solution having no buffering power, such as an aqueous sodium hydroxide solution and an aqueous hydrochloric acid solution, it is understood by those skilled in the art that if treatment with such a pH adjusting agent having no buffering power is sufficient for the pH requirement of the system, the pH adjusting agent having buffering power will more achieve the object of the present invention, and therefore these buffering agents can not only adjust the pH but also stabilize the pH. Thus, any of the pH adjusting agents listed herein or combinations thereof are included within the spirit and scope of the present invention.
When the freeze-dried powder injection is prepared, the content of solid matters in the prepared liquid medicine is 2-20% (w/v), preferably 3-15% (w/v), and more preferably 4-12%. Since lyophilized injectable powder is usually obtained by lyophilization in a vial, it is understood by those skilled in the art that the product usually takes the shape of a cake before the final product is obtained even before it is used by a doctor, although the volume of the cake is theoretically smaller (slightly smaller) than the volume of the original aqueous solution, usually the volume of the cake is not reduced to 50% of the volume of the original aqueous solution, usually the volume of the cake is between 80-120% of the volume of the original aqueous solution, more usually the volume of the cake is between 90-100% of the volume of the original aqueous solution, the volume of the aqueous solution of the freeze-dried composition before freeze-drying can be estimated from the liquid level trace of the raw aqueous solution (the liquid level trace remained on the wall of the vial after the main cake is reduced by freeze-drying, and even if the freeze-dried product in the vial is powdery due to various reasons such as collision, the original liquid level trace can be usually remained). Therefore, although the invention provides a substantially anhydrous freeze-dried powder injection, the volume of the liquid medicine at least before the start of freeze-drying can be roughly estimated according to the powder injection, and the content of the solid in the prepared liquid medicine can be calculated according to the estimated volume and the weight of the dried final product in a penicillin bottle when the freeze-dried powder injection is prepared. Therefore, the solid content of the liquid medicine in the freeze-dried powder injection according to the first aspect of the invention is 2-20% (w/v), preferably 3-15% (w/v), and more preferably 4-12%.
The term "solid content" means that the solid substance (e.g. the active compound of the invention and all excipients used, weight/g) is added to a solvent (e.g. water for injection) and dissolved to give a solution, the weight of the solid substance being divided by the percentage of the final solution volume (weight/volume percentage, e.g. g/100 ml). For example, in the present invention, 10g of the total weight of the active compound and the solid excipients is added with a proper amount of water solution for injection to prepare a solution with a final volume of 100ml, and the solid content is 10%.
In the present invention, the symbol%, depending on the context in which it is used, may have a meaning that is readily understood by a person skilled in the art. For example, where reference is made to solids content, the symbol indicates weight/volume percent (w/v, e.g., g/100 ml); also for example, where reference is made to "water content" in a freeze-dried powder injection, for example, the water content is below 8%, then the symbol% indicates weight/weight percent (w/w, g/100 g). Generally,% means weight/volume percent when a solid is dispersed in a liquid; where a solid is dispersed in a solid or a liquid is dispersed in a solid (e.g., the moisture content of a powder injection),% means weight/weight percent. In other cases, the symbol% represents weight/weight percent, unless otherwise indicated.
In preparing the drug solution of the present invention, it is known to those skilled in the art that rough filtration may be performed using, for example, a microfiltration membrane of about 0.45um, and fine filtration may be performed using, for example, a microfiltration membrane of about 0.22um to sterilize before filling the drug solution into vial, and that filtration may be performed several times if necessary.
The freeze-dried powder injection is freeze-dried powder injection. In one embodiment, the lyophilized powder for injection is a single dose formulation (e.g., vial-loaded powder for injection) and the amount of active compound in each unit dose may be, for example, but not limited to, about 10mg, about 20mg, about 30mg, about 45mg, about 50 mg.
The freeze-dried powder injection is dissolved again by water for injection, and the dissolving time is usually within 30 seconds, preferably within 20 seconds, and more preferably within 15 seconds. Such reconstitution rates are also generally expected in the art.
The freeze-dried powder injection provided by the invention can be stored in a dry place below 25 ℃ for at least 24 months, and can meet the storage requirements of common freeze-dried powder injection.
Papaverine is an opioid alkaloid which is a vasodilator and has direct nonspecific relaxation effects on blood vessels, heart or other smooth muscles.
Papaverine has effect in resisting vasospasm. Animal experiment shows that papaverine can relieve cerebral vasospasm obviously, and papaverine has dilating effect on non-spasm and spasm cerebral artery and preventing and treating spasm of other blood vessels. An animal model of a Delayed Cerebral Vasospasm (DCVS) dog following subarachnoid hemorrhage caused by 2 injections of fresh autologous arterial blood through the foramen magnum was used by researchers. Nimodipine is prepared into 10-6The molar concentration of papaverine is 10-4At mol/L concentration, two different vasodilator drugs were applied directly to the basal arteries of normal and DCVS dog animal models. As a result, nimodipine and papaverine have obvious expansion effect on spastic artery (Q is 19.2744, P)<0.01) but nimodipine has no dilating effect on the spastic artery of the DCVS dogs and papaverine has a mild dilating effect on the spastic artery. The results show that papaverine has an expansion effect on both non-spasm and spasm arteries, but the time for the blood vessel expansion effect is short, so that researchers establish a delayed cerebral vasospasm model of rabbits, perform intravascular treatment on the 4 th day and the 7 th day after subarachnoid hemorrhage respectively, and observe the content change of endothelin 1(ET-1) in blood plasma and cerebrospinal fluid (CSF) before and after the treatment. As a result, the ET-1 content in plasma and CSF of the group with 24h neurologic deficit symptom improvement (effective group) after intravascular treatment in two groups of animals is remarkably reduced (P) compared with that before treatment<0.01); no significant change in ET-1 content (P) before and after treatment in the group without improvement of neurological deficit symptoms (null group)>0.05). The conclusion shows that the treatment of the delayed cerebral vasospasm of the rabbits by injecting papaverine into the vertebral artery of the rabbits is effective, and the content change of ET-1 in blood plasma and CSF before and after treatment has obvious correlation with the curative effect of the method. The researchers adopt the pillow big pool to injectEstablishing rabbit cerebral vasospasm animal models in autologous arterial blood, dividing the rabbit cerebral vasospasm animal models into 4 groups, respectively administering different drugs through internal carotid artery, peripheral artery and vein, respectively measuring Blood Flow Velocity (BFV) of intracranial segment of internal carotid artery and intracranial segment diameter of internal carotid artery before, 3 days and 14 days after subarachnoid hemorrhage (SAH) formation, and observing pathological changes of intracranial segment of internal carotid artery and cerebral tissue under a light microscope. The results show that the BFV of the papaverine carotid artery injection group is obviously reduced, the tube diameter is increased and the pathological change is the lightest compared with the BFV of the papaverine intravenous injection group, the nimodipine artery injection group or the intravenous injection group. The conclusion shows that the spasmolytic effect of papaverine injected through internal carotid artery in late stage is better than that of papaverine injected through vein, and also better than that of nimodipine injected through artery or vein. Researchers use an elastic infusion pump (CPA) to directly and slowly inject papaverine and lidocaine into the periphery of the femoral artery anastomotic stoma of the rabbit continuously for 3-4 times every day, and the local tissue change is observed for 6h, 1, 3, 5 and 7d after operation, so that the occurrence situation of femoral artery spasm can be known according to the change of the diameter of the femoral artery and the thrombosis situation. The results show that after ice cold compress and fumigation treatment for 30min, the diameter change of the femoral artery of the rabbits in the group A (local administration) and the group B (intramuscular injection) is smaller, the diameter of the femoral artery of the rabbits in the group C (local normal saline) is reduced by 30-40% compared with the normal diameter, the rabbits are in a spastic state, and the difference between the group A and the group B and the group C has statistical significance; 20 femoral arteries of group A were unobstructed after transvascular anastomosis, 19 vessels of group B were unobstructed, and 16 vessels of group C were unobstructed. Administration of papaverine and lidocaine around the microangiostomy orifice using a PCA pump is believed to be effective in preventing and treating vasospasm. Researchers have used a secondary occipital cisterna hemopoiesis method to prepare a Japanese big ear white rabbit symptomatic cerebral vasospasm model, and papaverine is continuously infused through a side vertebral artery by a micro-pump. Results sustained infusion of papaverine 2, 5d basal arteriography diameter and grade of symptoms of nervous system lesions were significantly improved compared to pre-treatment (P)<0.01), no significant improvement in the control group (P)>0.05). The structures of the basilar artery and the brain tissue of the control group are obviously changed, and the treatment group is basically normal. Continuous arterial infusion of papaverine is thought to have a prophylactic effect on delayed cerebral vasospasm. The rabbit SAH model was prepared by craniotomy via frontotemporal craniotomy and 2 anterior blood injections in the Willis loop. Caused by the modelThe occurrence rate of cerebral vasospasm reaches 100%, the water content in brain tissue is increased to different degrees after SAH, and the Basilar Artery (BA) is also pathologically changed to different degrees. The content of Interleukin (IL) -6 in serum is obviously increased at 3 days, reaches a peak at 7 days, and still maintains a higher level at 14 days after SAH; the Tumor Necrosis Factor (TNF) -alpha content did not change significantly over time. After papaverine treatment, the spastic artery has obvious expansion and early treatment effect, the IL-6 content in the serum of the treatment group is lower than that of the SAH group at the same period, and the difference of the TNF-alpha content in each group has no statistical significance. And (4) conclusion: papaverine has definite curative effect on CVS after SAH treatment, can obviously dilate blood vessels, relieve ischemic cerebral edema and pathological changes, has more obvious effect on early treatment after SAH, and has positive correlation between the IL-6 level in serum and the CVS degree, thus prompting that certain relation exists between immune inflammatory response and CVS. The combined use of immunosuppressants in the early stage is expected to further improve the efficacy of papaverine in the treatment of CVS.
Not only animal experiments prove that papaverine has the function of resisting vasospasm, but also pharmacological research and clinical research also draw the same conclusion. In 19 patients with non-extracorporeal circulation coronary artery bypass surgery (OPCAB), a researcher obtains a self radial artery by using a non-contact surgical technology, and an untreated far section is reserved for 0.8-1.5 cm. The antispasmodic effect and the spasmodic effect of different preservation solutions are compared by applying the vascular periperfusion technique (organ bath). The blood vessel ring perfusion experiment shows that in the aspect of the relaxation capacity of the radial artery in a spastic state, the papaverine solution can relax blood vessels by 100% within 10min, and after the radial artery is soaked for 45-60 min in advance, the blood vessel preservation solution can effectively prevent the spasm of the isolated radial artery, and the papaverine solution is considered to have a good anti-vasospasm effect. 36 patients were divided into 2 groups, one group was irrigated with nimodipine and one group with papaverine. In the operation, Doppler probe is adopted to detect and separate blood flow velocity change of middle cerebral artery 10min before lateral fissure, before nimodipine or papaverine surgical field irrigation, and after nimodipine or papaverine surgical field irrigation. The results show that the blood flow velocity of the middle cerebral artery before and after the lavage of the two groups of nimodipine and papaverine in the operation is obviously reduced, but the difference between the two groups has no statistical significance for relieving the vasospasm. And (4) conclusion: nimodipine is safe and effective in lavage with papaverine operation, and can remarkably relieve vasospasm of middle cerebral artery.
Papaverine has effect in dilating blood vessel. Animal experiment research shows that papaverine has the function of dilating blood vessel, and this is significant in raising operation effect. In contrast to systemic administration of papaverine and intracapsular introduction of 2 types of papaverine and conventional expansion, the difference in tissue blood flow and expansion flap survival length between before and after expansion and before and after administration was observed when papaverine cream was applied to the tissue expansion process using a small pig as an experimental animal. The results show that the skin blood flow value of the external group before the water injection expansion is obviously higher than that of other groups (P is less than 0.05); the topical group remained at a higher level (P <0.01) than the other groups after expansion; the skin blood flow value of the external group before administration is higher than that of the other two groups (P < 0.05); the average flap survival length of the post-operation 10d external application group has statistical significance with the difference between the lead-in group, the intramuscular injection group and the control group (P is less than 0.01); the average content of papaverine in the dilated capsule tissue of the external application group is (3.5 +/-1.2) mg/g, and papaverine content cannot be detected in the membrane tissue of other groups and the blood of animals of each group. And (4) conclusion: the external papaverine cream can penetrate through the skin and effectively play a role in expanding blood vessels, so that the blood flow of the expanded skin is increased, the survival length of an expanded flap is increased, and the external papaverine cream has important application values in expanding the application range of tissue expansion, reducing complications and improving the operation effect. The researchers used the organ bath method to study the vascular ring of the great saphenous vein which is soaked by bicarbonate buffer solution (KH), KH containing 0.1mol/L of niceridol and KH containing 1.2mol/L of papaverine for 1h, and the vasoconstriction and relaxation reaction which is triggered after the three components are balanced is detected. As a result, it was found that the vascular rings in KH containing 0.1mol/L of niceradil and KH containing 1.2mol/L of papaverine were better in relaxation than those of the vascular rings immersed in the bicarbonate buffer alone, and the difference between them was not statistically significant. The endothelial cells of blood vessels soaked in the papaverine-containing solution have severe damage as seen by electron microscopy. And (4) conclusion: nicorandil and papaverine have good relaxation function on great saphenous vein bridges in coronary artery bypass grafting, and papaverine damages vascular endothelium.
Papaverine has analgesic effect. Researchers have used papaverine with different concentrations in combination with bupivacaine as brachial plexus anesthesia to study the blocking effect on pain sensation and exercise. The method comprises the following steps: 175 hospitalized patients without upper limb nerve, tendon and metacarpophalangeal joint injury were randomly divided into 5 groups by double-blind method: the control group (group 1) was anesthetized with bupivacaine (1.5mg/kg) at a mass fraction of 0.05. Observation groups (2-5 groups) were prepared by adding papaverine 0.25, 0.125, 0.0625, and 0.03125g/L to bupivacaine. Axillary plexus of the axillary road and brachial plexus are selected and used for puncture anesthesia administration. The results show that compared with the control group, the onset time of the 2-5 groups is gradually shortened in sequence, and the maintenance time is sequentially prolonged (P is less than 0.05); the degrees of muscle contraction and joint range of motion retardation gradually increased in this order, but were all weaker than those in group 1. And (4) conclusion: papaverine has effect in antagonizing bupivacaine, can accelerate the time of blocking brachial plexus pain sensation nerve fiber, has slight effect on motor nerve fiber, and has positive correlation between drug effect and concentration. Animal experiments also show that papaverine has significant analgesic effect. Researchers have observed the analgesic effect of oripavine by mouse writhing, hot plate, formaldehyde test and electrical stimulation. The result shows that the norargemonine can obviously reduce the times of mouse writhing reaction caused by potassium antimonite, improve the threshold value of mouse pain reaction by a 55 ℃ hot plate method, reduce the integral of mouse formaldehyde experiment pain reaction, and the half effective dose (ED50) of the analgesia effect of the mouse by an electrical stimulation method is 10.7 (8.2-12.9) mg/kg. And (4) conclusion: the norargemonine has remarkable analgesic effect. The analgesic mechanism of papaverine is still under further study. Researchers have studied the analgesic effect and mechanism of oripavine (Nu) by a mouse formaldehyde-induced pain model. The result shows that the compound has obvious inhibition effect on phase II pain reaction of formaldehyde pain reaction; the high dose also has certain inhibition effect on phase I pain response; its analgesic effect is not antagonized by naloxone. The analgesic effect of Nu can be partially inhibited by carbon monoxide (NO) containing precursor L-arginine, and the analgesic effect of Nu can be enhanced by Nitric Oxide Synthase (NOS) inhibitor L-NAME. The results suggest that the analgesic effect of Nu is not mediated by the endogenous endorphin system, but may be achieved by inhibiting inflammatory mediators such as NO, which are involved in the pain response, and the exact mechanism of which remains to be further studied. Researches of researchers prove that the norargemonine has a remarkable analgesic effect, the opium antagonist naloxone can completely antagonize the analgesic effect of morphine, but cannot change the effect of the norargemonine, and the analgesic effect of the norargemonine is unrelated to an endogenous opium system. HX arginine can partially inhibit the analgesic effect of the opipramine, and HX nitro arginine methyl ester has certain enhancing effect on the analgesic effect of the opipramine. It is believed that analgesia by norargemonine may be related in part to the inhibition of the production and release of NO.
Papaverine has pharmacological action of accelerating tissue expansion. Animal experiments show that the externally applied papaverine is an auxiliary tissue expansion mode which can effectively improve the tissue expansion efficiency. Some researchers use miniature pigs as experimental animals and divide the experimental animals into a medication expansion group and a conventional expansion group, wherein papaverine cream is externally applied to the medication expansion group in the tissue expansion process, the expansion time and the expansion capacity which can be increased each time are observed in both groups, and a skin test piece is taken after the expansion is finished to measure the stress-strain. As a result, the mean expansion time of the drug-expanded group was significantly shortened as compared with the conventional expanded group, and the viscoelasticity of the soft tissue of the skin tended to be increased and enhanced as compared with the conventional expanded group. Topical papaverine is believed to tend to increase and enhance the viscoelasticity of the dilated tissue, which accelerates tissue dilation and is an auxiliary tissue dilation method that effectively increases tissue dilation efficiency. The externally applied papaverine cream is considered to be capable of achieving effective drug concentration in tissues and inhibiting the function of expanding myofibroblasts in envelopes, thereby increasing average water injection amount, shortening expansion time, improving expansion efficiency and increasing the survival length of expanded skin flaps. The effect is continuous and lasting, the wound and infection chances are not increased, and the method is a safe, effective, simple, convenient and reliable auxiliary tissue expansion mode.
Papaverine has physiological effect on postoperative late contracture of autologous free skin graft. Animal experiments show that the externally applied papaverine cream can inhibit postoperative contracture of autologous free skin grafting and improve skin grafting efficiency. A researcher prepares 10 wound surfaces of 2cm multiplied by 2cm on the two sides of the back of each miniature pig, takes 2cm multiplied by 2cm fault skin sheets from the abdomen of an animal and plants the fault skin sheets on the wound surface of the back, stitches are removed 2 weeks after the operation, and 12 pairs of skin sheets which are 100 percent of the same animal and are alive and are positioned right and left opposite are taken and divided into two groups, namely a papaverine treatment group and a blank cream control group according to the left side and the right side. From the day of removing stitches, the group A is externally coated with 2% papaverine cream for 2 times every day, the group B is only coated with blank control cream, and the shrinkage rates of the two groups of skin grafts in 1, 3,4, 5 and 6 months after survival and the histological difference of the two groups of skin grafts in 6 months after survival are observed after measurement. As a result, the shrinkage of the skin graft in group A was significantly reduced compared to that in group B, and the difference between the two groups was statistically significant (P < 0.05). Tissue section display: the fibroblast of the graft in the group A is obviously reduced compared with that in the group B, the number of the microvascular is more than that in the group B, and the difference between the two groups has statistical significance (P is less than 0.05). And (4) conclusion: the externally applied papaverine cream can inhibit postoperative contracture of autologous free skin grafting tablets and improve skin grafting efficiency.
Papaverine has physiological effects on the microcirculation. There were researchers who selected 20 Wistar rats, randomly divided into two groups. Experimental groups: papaverine 3.18mg/kg, control group: 4ml of sodium chloride. Replicating the liver in-situ thermal ischemia reperfusion model according to the misra method, recovering the portal vein catheterization after reperfusion, and respectively administering papaverine and NaCl. As a result: the diameter of the hepatic central vein is narrowed (P <0.05), the blood flow speed is reduced (P <0.05) and the opening number of hepatic sinuses is reduced (P <0.05) in the warm ischemia reperfusion period compared with the diameter of the hepatic central vein before replication of the model. ② the diameter of the hepatic central vein is widened (P <0.05) after the drug is taken in the period of thermal ischemia reperfusion compared with that before the drug is taken, the blood flow speed is accelerated (P <0.05), and the opening number of hepatic sinuses is increased (P < 0.05). ③ the level of superoxide dismutase (SOD) in the experimental group is higher than that in the control group (P < 0.05); alanine Aminotransferase (ALT), aspartate Aminotransferase (AST), and lactate myohydrogenase (LDH) levels were lower than in the control group (P < 0.01). Optical microscopy: the liver sinus dilation degree is more obvious than that of the control group (P <0.05), and the degree of liver cell nepheloid degeneration and liver cell necrosis is less than that of the control group (P < 0.05). And (4) conclusion: firstly, serious microcirculation disturbance and reperfusion injury exist in the liver heat ischemia reperfusion period of rats; PAP can effectively improve the microcirculation disturbance of the rat in the liver heat ischemia reperfusion period and relieve liver tissue reperfusion injury; and the effect of improving liver microcirculation is definite and feasible when the medicine is administered through the portal vein in the reperfusion period of the living body.
Generally, the analgesic effect of papaverine is widely applied clinically, but the related mechanism research is not very deep, and the effect of relieving vasospasm is widely applied to surgery and clinical treatment of cerebrovascular diseases. Clinical observation on papaverine for treating penile erectile dysfunction is more, but the mechanism research is less, and other experimental researches also need to be further carried out.
In the present invention, the substance related to the papaverine or papaverine hydrochloride drug substance used or prepared in the present invention can be measured by the following high performance liquid chromatography (in the present invention, it may be abbreviated as HPLC method X), and the content of the main component or the content of impurities in the pharmaceutical composition or the intermediate of the preparation can also be measured/calculated by the HPLC method X. The HPLC method X is as follows:
measuring according to the specification of 0512 high performance liquid chromatography of the four parts of the 2015 edition of Chinese pharmacopoeia;
mixing solvent: acetonitrile/mobile phase a (20/80, v/v);
test solutions: for the raw material medicine, 20.0mg of a sample is dissolved in a mixed solvent, and then the mixed solvent is used for diluting to 10.0 mL; for the pharmaceutical composition, a test sample containing 20.0mg of papaverine hydrochloride is dissolved in a mixed solvent, and then diluted to 10.0mL by the mixed solvent;
reference solution (a): diluting 1.0mL of test solution to 100.0mL by using a mixed solvent, and then diluting 1.0mL of the test solution to 10.0mL by using the mixed solvent;
reference solution (b): dissolving 12mg of narcotine (impurity A) reference substance into 1.0mL of test solution, and then diluting the solution to 100.0mL by using a mixed solvent;
a chromatographic column: eclipse XDB-C8 column, 4.6X 250mm, 5 μm, 990967-; mobile phase: the pH of the mobile phase A which is 3.4g/L potassium dihydrogen phosphate solution is adjusted to 3.0 by dilute phosphoric acid, the mobile phase B is acetonitrile, and the mobile phase C is methanol; elution procedure:
flow rate: 1 mL/min;
detection wavelength of spectrophotometer: 238 nm;
sample introduction amount: 10 mu L of the solution;
relative retention time compared to papaverine (retention time 24.32 min): RRT of impurity E is 0.673, RRT of impurity C is 0.741, RRT of impurity B is 0.812, RRT of impurity a is 0.896, RRT of impurity F is 1.107, RRT of impurity D is 1.214;
and (3) testing the applicability of the system: using a reference solution (b) with a separation between the impurity a peak and the papaverine peak of not less than 1.5;
calculating the impurity content by comparing the main peak area of the reference solution (a) with the peak area of the impurity appearing in the test solution and combining a correction factor; in calculating the content, the peak areas of the following impurities were multiplied by the corresponding correction factors: impurity a ═ 6.2, impurity C ═ 2.7, and impurity D ═ 0.5 (the remaining impurities, if present, had a correction factor of 1).
For papaverine hydrochloride drug substances, the art generally requires that any impurities do not exceed the major peak area (i.e. < 0.1%) of the chromatogram of reference solution (a), and that the total impurities do not exceed 5 times the major peak area (i.e. < 0.5%) of the chromatogram of reference solution (a); both individual impurities and total impurities can often be suitably relaxed for the formulation.
Impurities:
among the impurities involved in the HPLC method A described above,
the impurity A, namely narcotine, is simultaneously used as an impurity for methodology investigation;
impurity B may be generated by papaverine degradation, and impurity D may be generated by further oxidation of impurity B (impurity D is usually also less present due to the small amount of impurity B in the raw material or formulation), so both formulations and compositions need to monitor impurity B, and if the rate of growth of impurity B in the formulation can be controlled, impurity D in the formulation does not need to be monitored;
while impurity C, E, F is a process intermediate impurity in the synthesis of bulk drugs, there is no need to monitor the formulation if the bulk drugs are able to effectively control their presence.
Therefore, it is necessary for the manufacturers of the preparations to additionally conduct the impurity B investigation of the preparations to determine the quality of the preparations, especially the stability thereof, after the raw materials are fully tested and qualified.
The invention generally provides a papaverine hydrochloride freeze-dried powder injection with excellent pharmaceutical properties, and the injection has excellent technical effects. The invention also provides a method for detecting the quality of the powder injection.
Detailed Description
The present invention will be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention. The present invention has been described generally and/or specifically with respect to materials used in testing and testing methods. Although many materials and methods of operation are known in the art for the purpose of carrying out the invention, the invention is nevertheless described herein in as detail as possible.
The following examples further illustrate the invention without limiting it. In the following examples, the pH adjuster (i.e., the pH adjuster in the present invention) is, as is not otherwise specified, a 1M sodium hydroxide solution or a 1M hydrochloric acid solution in such an amount that, when the powder injection is prepared, the pH of the solution prepared before freeze-drying is adjusted to a prescribed value or range, which is the value or range of the pH measured when the dry powder obtained by freeze-drying is diluted with water for injection to a solution containing 15mg/ml papaverine hydrochloride.
The following preparation steps are given for the purpose of illustration and are described in some detail based on the comparability of the examples, from which the process for the preparation of injection solutions according to the invention can be fully generalized by the person skilled in the art on the basis of the prior knowledge. In preparing various compositions in the following formulations, the total formulation amount of each batch was 1000ml, as not otherwise specified. However, the formula and preparation process of the tomamine are illustrated by the amount of 30mg of papaverine hydrochloride in each bottle, and the powder injection is prepared by subpackaging 30mg of active ingredients in each bottle.
The following injections were prepared under the corresponding GMP-requiring production conditions known to those skilled in the art. In the preparation of injections, papaverine hydrochloride was used as a commercially available drug substance (H63020084) as not otherwise specified.
The substance related to the drug substance (H63020084) was measured by HPLC method X, and the results were: impurity a was not detected, impurity B was 0.021%, impurity C was 0.031%, impurity F was 0.014%, impurity D and impurity E were not detected, all meeting the general requirement of < 0.1%.
Example 1: preparation of papaverine hydrochloride powder injection medicine composition
The formula is as follows:
the preparation method comprises the following steps:
(a) weighing papaverine hydrochloride and pharmaceutic adjuvant according to the prescription amount, adding a proper amount (65% of the prescription volume) of water for injection to dissolve, adding active carbon for injection accounting for 0.5% of the liquid medicine volume, stirring, filtering and decarburizing;
(b) adding water for injection to the prescribed amount, stirring uniformly, measuring the pH value of the solution and optionally measuring the content of active ingredients, and adjusting to the specified pH value by using an acid-base regulator if necessary;
(c) sterilizing and filtering the liquid medicine by using a microporous filter membrane, and filling the liquid medicine into a penicillin bottle;
(d) freeze drying to remove water, and pressing. The powder injection sample can be recorded as Ex 1.
Example 2: preparation of papaverine hydrochloride powder injection medicine composition
The formula is as follows:
the preparation method comprises the following steps:
(a) weighing papaverine hydrochloride and pharmaceutic adjuvant according to the prescription amount, adding a proper amount (accounting for 50% of the prescription volume) of water for injection to dissolve, adding active carbon for injection accounting for 0.5% of the liquid medicine volume, stirring, filtering and decarburizing;
(b) adding water for injection to the prescribed amount, stirring uniformly, measuring the pH value of the solution and optionally measuring the content of active ingredients, and adjusting to the specified pH value by using an acid-base regulator if necessary;
(c) sterilizing and filtering the liquid medicine by using a microporous filter membrane, and filling the liquid medicine into a penicillin bottle;
(d) freeze drying to remove water, and pressing. The powder injection sample can be recorded as Ex 2.
Example 3: preparation of papaverine hydrochloride powder injection medicine composition
The formula is as follows:
the preparation method comprises the following steps:
(a) weighing papaverine hydrochloride and pharmaceutic adjuvant according to the prescription amount, adding a proper amount (accounting for 90% of the prescription volume) of water for injection to dissolve, adding active carbon for injection accounting for 0.8% of the liquid medicine volume, stirring, filtering and decarburizing;
(b) adding water for injection to the prescribed amount, stirring uniformly, measuring the pH value of the solution and optionally measuring the content of active ingredients, and adjusting to the specified pH value by using an acid-base regulator if necessary;
(c) sterilizing and filtering the liquid medicine by using a microporous filter membrane, and filling the liquid medicine into a penicillin bottle;
(d) freeze drying to remove water, and pressing. The powder injection sample can be recorded as Ex 3.
Example 4: preparation of papaverine hydrochloride powder injection medicine composition
The formula is as follows:
the preparation method comprises the following steps:
(a) weighing papaverine hydrochloride and pharmaceutic adjuvant according to the prescription amount, adding a proper amount (accounting for 80% of the prescription volume) of water for injection to dissolve, adding active carbon for injection accounting for 0.4% of the liquid medicine volume, stirring, filtering and decarburizing;
(b) adding water for injection to the prescribed amount, stirring uniformly, measuring the pH value of the solution and optionally measuring the content of active ingredients, and adjusting to the specified pH value by using an acid-base regulator if necessary;
(c) sterilizing and filtering the liquid medicine by using a microporous filter membrane, and filling the liquid medicine into a penicillin bottle;
(d) freeze drying to remove water, and pressing. The powder injection sample can be recorded as Ex 4.
Example 5: preparation of papaverine hydrochloride powder injection medicine composition
The formula is as follows:
the preparation method comprises the following steps:
(a) weighing papaverine hydrochloride and pharmaceutic adjuvant according to the prescription amount, adding a proper amount (accounting for 70% of the prescription volume) of water for injection to dissolve, adding active carbon for injection accounting for 0.25% of the liquid medicine volume, stirring, filtering and decarburizing;
(b) adding water for injection to the prescribed amount, stirring uniformly, measuring the pH value of the solution and optionally measuring the content of active ingredients, and adjusting to the specified pH value by using an acid-base regulator if necessary;
(c) sterilizing and filtering the liquid medicine by using a microporous filter membrane, and filling the liquid medicine into a penicillin bottle;
(d) freeze drying to remove water, and pressing. The powder injection sample can be recorded as Ex 5.
Example 6: preparation of papaverine hydrochloride powder injection medicine composition
Referring to the formulation and preparation method of examples 1-5, respectively, except that no alanine was added, 5 kinds of powder injection samples were obtained and are respectively marked as Ex61, Ex62, Ex63, Ex64 and Ex 65.
Example 7: preparation of papaverine hydrochloride powder injection medicine composition
With reference to the formulation and preparation method of examples 1-5, 5 kinds of powder injection samples were obtained and recorded as Ex71, Ex72, Ex73, Ex74 and Ex75, respectively, except that no maltol was added.
Example 8: preparation of papaverine hydrochloride powder injection medicine composition
Referring to the formulation and preparation method of examples 1-5, respectively, except that neither alanine nor maltol was added, 5 kinds of powder injection samples were obtained and are respectively marked as Ex81, Ex82, Ex83, Ex84 and Ex 85.
Example 9: preparation of papaverine hydrochloride powder injection medicine composition
Referring to the formulas and preparation methods of Ex1, Ex61, Ex71 and Ex81 respectively, except that mannitol is not added, 4 powder injection samples are prepared and are marked as Ex91, Ex92, Ex93 and Ex94 respectively; refer to the formulas and preparation methods of Ex1, Ex61, Ex71 and Ex81 respectively, except that mannitol is replaced by lactose, and 4 kinds of powder injection samples are marked as Ex95, Ex96, Ex97 and Ex98 respectively.
In the above examples 1 to 9, the water reconstitution time for the powder injection obtained by using mannitol as an excipient was within a range of 16 to 29 seconds, and the water reconstitution time for the powder injection obtained by using lactose as an excipient was within a range of 68 to 85 seconds, which indicates that mannitol as an excipient is significantly superior to lactose.
Test example 1: stability of powder injection (API and content and variation of impurity B)
Sealing the powder for injection or raw materials in a glass bottle, simulating commercial package, and standing at 40 deg.C in dark for 6 months.
The content of active substances of each powder injection sample in 0 month and 6 months is determined by adopting an HPLC method X, the content of the active substances in 6 months is divided by the content of the active substances in 0 month for a certain sample to obtain the percentage as the residual content of the active substances, and the result is more than 90 percent, preferably more than 95 percent, more preferably more than 97 percent, which indicates that the active ingredients are stable, and the result is that: the residual content of active substances of Ex 1-Ex 5, Ex 61-Ex 65, Ex 71-Ex 75, Ex 81-Ex 85 and Ex 91-Ex 98 powder injections is within the range of 97.2-99.1%, and no obvious difference exists among the active substances, for example, the residual content of the Ex1 powder injection is 98.83%.
The content of the impurity B in each powder injection, crude drug and commercially available powder injection (H20060262) at 0 month and 6 months is determined by adopting an HPLC method X, and the percentage increase of the impurity B is calculated according to the following formula for each sample:
the percentage increase of impurity B was ═ [ (6 months impurity B content-0 months impurity B content) ÷ 0 months impurity B content ] × 100%.
The content of the impurity B in the bulk drug at 0 month is 0.021%, the content of the impurity B at 0 month in Ex 1-Ex 5, Ex 61-Ex 65, Ex 71-Ex 75, Ex 81-Ex 85, Ex 91-Ex 98 powder injection and the content of the impurity B at 0 month in the commercial powder injection are all in the range of 0.020-0.028%, for example, the content of the impurity B at 0 month in Ex1 powder injection is 0.023%, which indicates that the content of the impurity B in each powder injection after preparation is not obviously different from that of the bulk drug used in the powder injection, namely the content of the impurity B in the preparation process cannot be changed.
After 6 months of treatment, each sample showed significant differences in the percentage increase of impurity B, specifically: the percentage increase of the impurity B of the bulk drug is 53.2 percent; the addition percentages of impurities B of Ex 1-Ex 5 and Ex 91-Ex 98 powder injections are all within the range of 46-67% (for example, Ex1 is 58.6%), and the impurities B are only slightly increased and are all less than 0.04% and cannot exceed the limit of 0.1% in general; the percentage increase of impurities B in Ex 61-Ex 65, Ex 71-Ex 75, Ex 81-Ex 85 powder injections and commercial powder injections is in the range of 376-493% (for example, Ex61 is 412.4%), the increase is obvious, and part of samples exceed the common limit of 0.1%. Through identification, the auxiliary material of the powder injection sold in the market comprises mannitol. These results indicate that the combination of mannitol and API results in accelerated growth of impurity B during long-term storage of the powder injection; the invention adds another two kinds of conventional pharmaceutic adjuvants in the powder injection containing mannitol at the same time, can inhibit the growth trend of impurity B, namely poppy alcohol, of the powder injection in the long-term storage process remarkably, can not inhibit the growth of impurity B when only one or none of the impurities is added; although the limit of the impurity B in the powder injection is not clearly limited in the prior art, the Ex 1-Ex 5 are obviously more preferable and expected compared with other samples; these results are not at all expected by the prior art.
Test example 2: quality inspection of powder injection
The test example was conducted mainly in accordance with the regulations of national drug Standard WS 1-XG-023-2015.
Acidity: a proper amount of samples (Ex 1-Ex 5, Ex 61-Ex 65, Ex 71-Ex 75 and Ex 81-Ex 85 powder injection) are added with water to prepare a solution containing 30mg of active ingredients in each 1ml, and the pH value is usually required to be 2.5-4.0 in the field according to law determination (appendix VI H in the second part of 2010 edition of Chinese pharmacopoeia). The pH value of each powder injection is determined to be within the range of 2.5-4.0.
Clarity and color of the solution: samples (Ex 1-Ex 5, Ex 61-Ex 65, Ex 71-Ex 75 and Ex 81-Ex 85 powder injection) are added with new boiling water and are dissolved in cold water and diluted to prepare a solution containing 30mg of active ingredients in each 1ml, and the solution of the variety is generally required to be clear and colorless in the field; if the turbidity appears, the turbidity is not concentrated compared with the turbidity standard solution No.1 (appendix IX B of the second part of the 2010 version of the Chinese pharmacopoeia); if the color is developed, the color cannot be darker than the standard orange yellow No. 3 colorimetric solution (I IX A first method in the second appendix of the 2010 version of the Chinese pharmacopoeia). The clarity and color of the powder injection solution are determined to meet the specifications.
Moisture content: samples (Ex 1-Ex 5, Ex 61-Ex 65, Ex 71-Ex 75 and Ex 81-Ex 85 powder injection) are measured according to a moisture measurement method (I method A of appendix VIII M in the second part of 2010 edition of Chinese pharmacopoeia), and the moisture content of the product is generally required to be not more than 3.0 percent in the field. The water content of each powder injection is determined to meet the specification.
Bacterial endotoxin: samples (Ex 1-Ex 5, Ex 61-Ex 65, Ex 71-Ex 75 and Ex 81-Ex 85 powder injection) are taken, and the endotoxin content of each 1mg of papaverine hydrochloride of the variety is generally required to be less than 2.5EU in the field according to the Law inspection (appendix XI E of the second part of Chinese pharmacopoeia 2010 edition). The determination shows that the bacterial endotoxin of each powder injection meets the specification.
And (3) sterilization: taking the product, adding a proper amount of peptone water solution with 0.1% to dissolve, treating by a thin film filtration method, taking staphylococcus aureus [ CMCC (B) 26003 ] as a positive control bacterium, and checking according to law (appendix XI H of second part of Chinese pharmacopoeia 2010 edition), wherein the product is generally required to meet the specification in the field. The sterility of each powder injection is determined to meet the above specification.
Related substances are as follows: taking samples (Ex 1-Ex 5 powder for injection), diluting with mobile phase to obtain solution containing papaverine hydrochloride 1mg per 1ml as test solution; precisely measure 1ml, place in a 100ml measuring flask, dilute to the scale with mobile phase, shake well, as control solution. Precisely measuring 20 μ l of the reference solution according to the chromatographic conditions of the content measurement item, injecting into a liquid chromatograph, adjusting the detection sensitivity to make the peak height of the main component chromatographic peak about 20% of the full-scale range, precisely measuring 20 μ l of each of the sample solution and the reference solution, respectively injecting into the liquid chromatograph, and recording the chromatogram until the retention time of the main component peak is 3 times. The field generally requires that the chromatogram of the sample solution of the variety has impurity peaks, and the sum of the peak areas of the impurities is not larger than the main peak area (1.0%) of the control solution. The sterility of each powder injection is determined to meet the above specification. The method cannot obtain specific impurities and contents, and only can determine the total impurity amount.
In addition, the five samples of the powder injection Ex1 to Ex5 have no toxic effect which is not beneficial to human health when being subjected to acute, subacute and long-term toxicological experiments according to the general drug registration specifications.
Test example 3: determination of impurity C, F in powder injection
As described herein, there may be process intermediate impurities left in the papaverine hydrochloride drug substance, typically dihydropapaverine (which is also referred to as impurity C in the present invention) and amide impurities (which is also referred to as impurity F in the present invention), papaverine is difficult to degrade to form impurity C and impurity F, and thus, for the formulation manufacturer, the quality of the formulation can be controlled by detecting impurity C and impurity F of the drug substance without having to additionally perform impurity C, F detection on the formulation. However, it is sometimes necessary to detect impurities C and F in a preparation, for example, after the preparation product is marketed, when a market regulatory body evaluates the quality of the marketed product or performs a spot check, the preparation is directly detected without raw material data.
The inventor tries to measure the impurity C, F in the Ex 1-Ex 5 powder injection by using an HPLC method X, and finds that an obvious impurity exists at the position of relative retention time RRT of 0.727, the impurity is identified as maltol according to HPLC specificity, the maltol seriously influences the measurement and calculation of the impurity C, and the separation degree of the maltol is less than 1.5, so that the influence of the maltol in the preparation on the measurement of the impurity C is very necessary to be overcome.
This test example 3 provides an improved HPLC method for testing powder injections containing maltol, herein designated HPLC method Y, which differs from HPLC method X only in the method of preparation of the test solution, which is as follows:
placing a powder injection test sample containing 200.0mg of papaverine hydrochloride into a 25mL stoppered test tube, precisely adding 10mL of diethyl ether and 10mg of oxalic acid, sealing the test tube, carrying out vortex treatment for 25min, centrifuging, precisely measuring 1mL of supernatant, placing the supernatant into a 10mL measuring flask, volatilizing the supernatant, adding a mixed solvent to dissolve the supernatant, and diluting the supernatant to 10.0mL to obtain a test solution.
The HPLC method Y is used for measuring the impurities A, B, C, D, E, F of Ex 1-Ex 5 powder injections, and the result is that:
the maltol peak at RRT-0.727 disappeared, indicating that maltol was removed after treatment by the test solution formulation procedure of HPLC method Y;
5 powder injection impurities A are not detected; the content of 5 powder injection impurities B is basically the same as that of the HPLC method X (the difference of the two methods is in a range of +/-0.002 percent of the percentage unit) and is 0.021-0.025 percent, for example, the content of Ex1 powder injection impurity B is 0.022 percent;
the content of C impurities in the 5 powder injections is within the range of 0.030-0.033 percent and is matched with the content of C impurities in the bulk drugs used for preparing the powder injections by 0.031 percent;
5 powder injection impurities D and E are not detected;
the content of the impurity F of the 5 powder injections is within the range of 0.012-0.015 percent and is consistent with the content of the impurity F of the raw material medicines for preparing the powder injections by 0.014 percent;
these results indicate that HPLC Y can be effectively used to determine the content of each impurity in the powder injection.
In addition, the impurity C content in Ex1 to Ex5 powder injections was measured and calculated by HPLC method X and HPLC method Y, respectively, and the measurement was repeated 5 times with the test solution for each sample, and the relative standard deviation RSD of the measurement results was calculated. RSD of 5 powder injections by an HPLC method X is in a range of 7.46-9.13%, for example, RSD of 5 times of Ex1 is 8.27%; the RSD of Y in HPLC method for 5 kinds of powder injection is in the range of 0.93-1.27% Y, for example, the RSD measured for 5 times to Ex1 is 1.06%; the main reason influencing the precision of the HPLC method X is that the separation degree of the maltol RRT peak of 0.727 and the impurity C is insufficient, thereby influencing the calculation of the content of the impurity C.
Test example 3 a: referring to HPLC method Y of experimental example 3, except that the test solution was prepared using only ether without adding oxalic acid, the peak size of maltol at RRT of 0.727 was substantially the same as that using HPLC method X (the relative peak area compared to the experimental example 3 method was about 97.3%), indicating that maltol was not removed.
Test example 3 b: referring to HPLC method X except that 1mg of oxalic acid (previously added in proportion to the mixed solvent) was further added in the preparation of the test solution, the result was that the peak size of maltol at RRT of 0.727 was substantially the same as that using HPLC method X (the relative peak area compared with the result using HPLC method X of test example 3 was about 101.7%), indicating that maltol was not removed. Test example 3 c: referring to HPLC method Y, precisely measuring 1mL of vortex-treated supernatant, placing the vortex-treated supernatant into a 2mL measuring flask, volatilizing, adding a mixed solvent to dissolve and diluting to 2.0mL, and obtaining a treated test solution with the concentration of 5 times; the chromatogram showed a relatively small maltol peak at RRT 0.727, which was divided by 5 times and multiplied by 100% with the result of HPLC method X, resulting in 0.26%, i.e., the amount of RRT 0.727 in the test solution obtained by HPLC method Y was 0.26% of the amount in the test solution obtained by HPLC method X, and 99.74% of the maltol in the test solution was removed; this result reveals the reason why the measurement of impurity C can be prevented from being affected by HPLC method Y.
Therefore, the HPLC method Y can be used for determining the impurity A, B, C, D, E, F in the Ex 1-Ex 5 powder injection, and can be used for monitoring the change of the impurity B in the powder injection similar to the experimental example 1; HPLC method X is not suitable for determining impurity C in these powder injections.
The above-mentioned embodiments are merely preferred embodiments for fully illustrating the present invention, and the scope of the present invention is not limited thereto. The equivalent substitution or change made by the technical personnel in the technical field on the basis of the invention is all within the protection scope of the invention. The protection scope of the invention is subject to the claims.
Claims (11)
1. A method for the quality detection of a pharmaceutical composition in the form of a freeze-dried powder injection, comprising the determination of the content of impurity A, B, C, D, E, F in the powder injection by high performance liquid chromatography, comprising the following operations:
measuring according to the specification of 0512 high performance liquid chromatography of the four parts of the 2015 edition of Chinese pharmacopoeia;
mixing solvent: acetonitrile/mobile phase a in a volume ratio of 20/80;
test solutions: placing a powder injection test sample containing 200.0mg of papaverine hydrochloride into a 25mL stoppered test tube, precisely adding 10mL of diethyl ether and 10mg of oxalic acid, sealing, carrying out vortex treatment for 25min, centrifuging, precisely measuring 1mL of supernatant, placing the supernatant into a 10mL measuring flask, volatilizing, adding a mixed solvent to dissolve, and diluting to 10.0mL to obtain a test solution;
reference solution a: diluting 1.0mL of test solution to 100.0mL by using a mixed solvent, and then diluting 1.0mL of the test solution to 10.0mL by using the mixed solvent;
reference solution b: dissolving 12mg of impurity A, namely a narcotine reference substance, in 1.0mL of test solution, and then diluting the solution to 100.0mL by using a mixed solvent;
a chromatographic column: eclipse XDB-C8 column, 4.6X 250mm, 5 μm;
mobile phase: the pH of the mobile phase A which is 3.4g/L potassium dihydrogen phosphate solution is adjusted to 3.0 by dilute phosphoric acid, the mobile phase B is acetonitrile, and the mobile phase C is methanol;
elution procedure:
flow rate: 1 mL/min;
detection wavelength of spectrophotometer: 238 nm;
sample introduction amount: 10 mu L of the solution;
the relative retention times compared to papaverine are: RRT =0.67 ± 0.02 of impurity E, RRT =0.74 ± 0.02 of impurity C, RRT =0.81 ± 0.02 of impurity B, RRT =0.90 ± 0.02 of impurity a, RRT =1.11 ± 0.02 of impurity F, RRT =1.21 ± 0.02 of impurity D;
and (3) testing the applicability of the system: using a reference solution b, the separation degree between the impurity A peak and the papaverine peak is not less than 1.5;
calculating the content of the impurity A, B, C, D, E, F by comparing the main peak area of the reference solution a with the peak area of the impurity appearing in the test solution and combining a correction factor; in calculating the content, the peak area of the impurity, if present, is multiplied by its corresponding correction factor: impurity a =6.2, impurity C =2.7, impurity D =0.5, the remaining impurities, if present, having a correction factor of 1;
impurities B, C, D, E, F are respectively:
the pharmaceutical composition comprises hydrochloride papaverine and pharmaceutic adjuvants, wherein the pharmaceutic adjuvants comprise mannitol, edetate, alanine and maltol, and the weight ratio of papaverine to mannitol is 30: 15-500, wherein the weight ratio of papaverine to edetate is 30: 2-10, wherein the weight ratio of papaverine to alanine is 30: 10-20, wherein the weight ratio of papaverine to maltol is 30: 2-10; the solid content of the medicinal composition in a solution before freeze drying is 3-15%, and the prepared liquid medicine is sterilized by a microporous filter membrane filtration mode before freeze drying.
2. The method of claim 1, wherein the relative retention time of each impurity compared to papaverine is: RRT =0.673 for impurity E, RRT =0.741 for impurity C, RRT =0.812 for impurity B, RRT =0.896 for impurity a, RRT =1.107 for impurity F, and RRT =1.214 for impurity D.
3. The method of claim 1, wherein the papaverine has a retention time of 24 ± 1 min.
4. The method of claim 1, wherein edetate is selected from disodium edetate, calcium sodium edetate.
5. A pharmaceutical composition comprises hydrochloride papaverine and pharmaceutic adjuvants, wherein the pharmaceutic adjuvants comprise mannitol, edetate, alanine and maltol, and the weight ratio of papaverine to mannitol is 30: 15-500, wherein the weight ratio of papaverine to edetate is 30: 2-10, wherein the weight ratio of papaverine to alanine is 30: 10-20, wherein the weight ratio of papaverine to maltol is 30: 2-10; the pharmaceutical composition is a freeze-dried powder injection, the solid content of the solution before freeze drying is 3-15%, and the prepared liquid medicine is sterilized by a microporous filter membrane filtration mode before freeze drying.
6. The pharmaceutical composition of claim 5, wherein edetate is selected from disodium edetate, calcium sodium edetate.
7. The pharmaceutical composition according to claim 5, further comprising an acid-base modifier in an amount such that when the water for injection of the lyophilized powder for injection is dissolved to a solution containing papaverine hydrochloride at a concentration of 15mg/ml, the pH of the solution is within a range of 2.5 to 4.0.
8. The pharmaceutical composition according to claim 5, further comprising an acid-base modifier in an amount such that when the water for injection of the lyophilized powder for injection is dissolved to a solution containing papaverine hydrochloride at a concentration of 15mg/ml, the pH of the solution is within a range of 3.0 to 4.0.
9. The pharmaceutical composition of claim 7, which is prepared by the steps comprising:
(a) weighing papaverine hydrochloride and pharmaceutic adjuvant according to the prescription amount, adding a proper amount of water for injection to dissolve, adding active carbon, stirring, filtering and decarburizing;
(b) adding water for injection to the prescription amount, stirring uniformly, measuring the pH value of the solution and optionally measuring the content of active ingredients, and adjusting the pH value to 2.5-4.0 by using an acid-base regulator;
(c) sterilizing and filtering the liquid medicine by using a microporous filter membrane, and filling the liquid medicine into a penicillin bottle;
(d) freeze drying to remove water, and pressing;
wherein,
the step (a) of adding a proper amount of water for injection refers to adding water for injection accounting for 50-90% of the volume of the prescription,
the filtered filtrate obtained in the step (c) has a solid content of 2-20% by weight/volume.
10. The pharmaceutical composition of claim 9, wherein the filtered filtrate from step (c) has a solids content of 3-15% w/v.
11. The use of alanine and maltol in combination for the preparation of a pharmaceutical composition for injection of a lyophilized powder injection of papaverine hydrochloride, said alanine and maltol being used in combination to inhibit the rate of growth of alcoholic impurities in the pharmaceutical composition; the pharmaceutical composition is as claimed in any one of claims 5 to 10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010822009.6A CN111796043B (en) | 2020-08-15 | 2020-08-15 | Papaverine hydrochloride powder injection for injection and quality detection method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010822009.6A CN111796043B (en) | 2020-08-15 | 2020-08-15 | Papaverine hydrochloride powder injection for injection and quality detection method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111796043A CN111796043A (en) | 2020-10-20 |
CN111796043B true CN111796043B (en) | 2022-02-22 |
Family
ID=72834511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010822009.6A Active CN111796043B (en) | 2020-08-15 | 2020-08-15 | Papaverine hydrochloride powder injection for injection and quality detection method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111796043B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113143868B (en) * | 2021-03-03 | 2022-04-12 | 海南久常制药有限公司 | Papaverine hydrochloride for injection and preparation method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4126615A (en) * | 1975-12-12 | 1978-11-21 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt | Process for the manufacture of pure isoquinoline derivatives |
SU830238A1 (en) * | 1979-07-17 | 1981-05-15 | Иркутский Государственный Медицинскийинститут | Method of determining papaverine hydrochloride of medicinal mixtures |
CN104254251A (en) * | 2012-04-26 | 2014-12-31 | 洲际大品牌有限责任公司 | Confectionery composition, method therefor, and associated confectionery articles |
CN104458987A (en) * | 2014-11-26 | 2015-03-25 | 公安部禁毒情报技术中心 | Method for detecting 25 neutral or acidic impurities in heroin |
CN106468690A (en) * | 2016-09-05 | 2017-03-01 | 山东世通检测评价技术服务有限公司 | A kind of method measuring papaverine and narcotine in prepared food meat productss |
CN106706789A (en) * | 2016-12-26 | 2017-05-24 | 江苏联环药业股份有限公司 | Method for detecting related substances in drotaverine hydrochloride injection by high performance liquid chromatography |
WO2020037271A1 (en) * | 2018-08-17 | 2020-02-20 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
-
2020
- 2020-08-15 CN CN202010822009.6A patent/CN111796043B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4126615A (en) * | 1975-12-12 | 1978-11-21 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt | Process for the manufacture of pure isoquinoline derivatives |
SU830238A1 (en) * | 1979-07-17 | 1981-05-15 | Иркутский Государственный Медицинскийинститут | Method of determining papaverine hydrochloride of medicinal mixtures |
CN104254251A (en) * | 2012-04-26 | 2014-12-31 | 洲际大品牌有限责任公司 | Confectionery composition, method therefor, and associated confectionery articles |
CN104458987A (en) * | 2014-11-26 | 2015-03-25 | 公安部禁毒情报技术中心 | Method for detecting 25 neutral or acidic impurities in heroin |
CN106468690A (en) * | 2016-09-05 | 2017-03-01 | 山东世通检测评价技术服务有限公司 | A kind of method measuring papaverine and narcotine in prepared food meat productss |
CN106706789A (en) * | 2016-12-26 | 2017-05-24 | 江苏联环药业股份有限公司 | Method for detecting related substances in drotaverine hydrochloride injection by high performance liquid chromatography |
WO2020037271A1 (en) * | 2018-08-17 | 2020-02-20 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
Non-Patent Citations (4)
Title |
---|
DEVELOPMENT OF A NEW HPLC METHOD FOR DETERMINATION OF PAPAVERINE IN PRESENCE OF ITS PHOTOOXIDATION PRODUCTS;Irinel A. Badea 等;《Analytical Letters》;20101231;第43卷;1217-1229 * |
Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis;Vishal M Gohil 等;《Nature Biotechnology》;20100214;第28卷(第3期);249-255 * |
复方氯化铵甘草口服溶液的制备及其麻醉成分分析;秦喜顺 等;《中国医院药学杂志》;20090831;第29卷(第16期);1400-1401 * |
盐酸罂粟碱注射液含量测定及有关物质研究;王瑶等;《药物分析杂志》;20111231;第31卷(第09期);1693-1698 * |
Also Published As
Publication number | Publication date |
---|---|
CN111796043A (en) | 2020-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111848512B (en) | Powder injection pharmaceutical composition prepared from high-purity papaverine hydrochloride | |
JP5406197B2 (en) | Co-solvent compositions and methods for improving delivery of dantrolene therapeutics | |
JP7042531B2 (en) | Pharmaceutical composition containing deoxycholic acid | |
JP6284945B2 (en) | Freeze-dried melphalan flufenamide | |
TWI763632B (en) | Methods of sedation and parenteral formulation for use during critical care treatment | |
EP2952184B1 (en) | Pharmaceutical formulation for treating pancreatic cancer | |
JP6818019B2 (en) | Injectable pharmaceutical composition of lefamulin | |
WO2019006741A1 (en) | Preparation of pulsatilla saponin b4 for injection | |
WO2008119260A1 (en) | A medicinal composition of carmustine, preparation method and application | |
CN111796043B (en) | Papaverine hydrochloride powder injection for injection and quality detection method thereof | |
CN110870869A (en) | Pharmaceutical composition comprising carbohydrate nutrients and conventional ineffective compounds and use thereof | |
CN111789818B (en) | Papaverine hydrochloride pharmaceutical composition for injection and preparation method thereof | |
US20230414617A1 (en) | Pharmaceutical composition comprising acid-base neutralization combination and application thereof | |
CN101317846B (en) | Tetrodotoxin formulation for drug rehabilitation , pain ease | |
WO2016110225A1 (en) | Sulfonamide pharmaceutical composition | |
CA2572167A1 (en) | Quinolone-containing medicinal composition | |
WO2010031346A1 (en) | Freeze-dried preparation of tetrodotoxin and the producing method thereof | |
CN101891751B (en) | Method for preparing tetrodotoxin | |
US6150420A (en) | Method for enhanced brain delivery of bupropion | |
CN110870858A (en) | Pharmaceutical compositions comprising organic acid acidifying agents and conventional ineffective compounds and uses thereof | |
WO2004098614A1 (en) | Freeze-dried preparation containing methylcobalamin and process for producing the same | |
CN110870860A (en) | Pharmaceutical composition comprising amino acid nutrients and conventional ineffective compounds and use thereof | |
CN104800172A (en) | Carbazochrome sodium sulfonate powder injection for injection and preparation method thereof | |
WO2014059363A1 (en) | Oral solution formulations of aripiprazole | |
US20220401366A1 (en) | Long acting nmda antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |